Neural Control of Gait & Navigation in ADRD
University of Florida · with National Institute on Aging (NIA) · NCT06501820
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 65–89 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 60
- US sites recruiting
- 1
- Study start
- November 13, 2025
- Record last updated
- July 31, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Brain network segregation, or independent functioning, declines with age and is associated with slower walking speed. Here, the investigators will determine the extent to which brain vestibular network segregation can be altered with bilateral vestibular cortical transcranial direct current stimulation (tDCS) in older adults with subjective cognitive decline. Participants will be randomly assigned to an active or sham stimulation condition. They will receive three, 20-minute sessions of tDCS while they are walking and performing cognitive tasks. MRI of the brain will be acquired before and after these three sessions.
Being studied: Transcranial direct current stimulation
Conditions: Aging
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Community dwelling men and women 18-35 years old or 65-89 years old
- Ability to walk unassisted for ten minutes
- Willingness to undergo all testing procedures
- English speaking Additional Inclusion Criteria for those with SCD
- Subjective report of cognitive complaints with scores >16 on the Cognitive Change Index (CCI-20), a validated scale of subjective cognitive decline (Saykin et al., 2013). This scale consists of 20 items that are rated on 5 point Likert scale, where 1= "Normal: No change compared to 5 years ago", 3= "Mild Problem: Some change compared to 5 years ago) and 5="Severe Problem: Much worse compared to 5 years ago".)
- No evidence of dementia or mild cognitive impairment based on cognitive screening (i.e., Montreal Cognitive Assessment (MoCA) score within normal limits for age, education and sex using the NACC Uniform Data Set (UDS) norms (Weintraub et al., 2018)[119]
- No psychometric evidence of cognitive impairment based on performance on the Neuropsychological Battery from the NACC Unified Data Set, version 3[119]. The battery includes measures of attention, recent memory, language, visuospatial, and executive function. Norms are available for over 3600 older adults [119]. Scores on these measures cannot be lower than 1.0 SD (16th %ile) below normative values based on age, education, and gender.
- Reading at > 8th grade level based on the reading subtest of the Wide Range Achievement Test- IV.
- Global Clinic Dementia Rating (CDR) score must be 0 [156]
- Family history of dementia/probable Alzheimer's disease in first degree relative (parents, children, siblings)
- Normal functional behavior in terms of daily activities, based on the Functional Activities Scale[122]
- In line with recommendations of SCD task force (Molienueva et al., 2017)[116] an informant must be available for two reasons: a) to provide information about the participant's complaints using the informant version of the CCI-20, and b) to corroborate normal IADL's on the Functional Activity Questionnaire[120] .
Exclusion Criteria
- Significant medical event requiring hospitalization in the past 6 months that has the potential to contaminate data being collected (fracture, hospitalization etc.)
- Severe visual impairment or corrected visual acuity less than 20/40, which would preclude completion of the assessments
- Inability to undergo brain imaging due to claustrophobia or implants such as pacemakers, heart valves, brain aneurysm clips, orthodontics, non-removable body jewelry, or shrapnel containing ferromagnetic metal
- tDCS ineligibility for Aim 3 (history of epilepsy, medications that alter cortical excitability, etc.)
- History of stroke
- Any history of clinically diagnosed traumatic brain injury resulting in > 1 minute loss of consciousness
- Any major ADL disability (unable to feed, dress, bath, use the toilet, or transfer)
- Report of lower extremity pain due to osteoarthritis that significantly limits mobility
- Diagnosis or treatment for rheumatoid arthritis
- Known neuromuscular disorder or overt neurological disease (e.g. Multiple Sclerosis, Rhabdomyolysis, Myasthenia Gravis, Ataxia, Apraxia, post-polio syndrome, mitochondrial myopathy, Parkinson's Disease, ALS etc.)
- Unable to communicate because of severe hearing loss or speech disorder
- Planned surgical procedure or hospitalization in the next 12 months (joint replacement, coronary artery bypass graft, etc.)
- Severe pulmonary disease, requiring the use of supplemental oxygen
- Terminal illness, as determined by a physician
- Severe cardiac disease, including NYHA Class III or IV congestive heart failure, clinically significant aortic stenosis, recent history of cardiac arrest, use of a cardiac defibrillator, or uncontrolled angina
- Is planning to move out of the area during the follow up period
- Use of walker or wheel chair
- Failure to provide informed consent
Recruiting US locations
University of Florida
Gainesville, FL 32611
Site contact: Rachael Seidler · 734-834-0385 · rachaelseidler@ufl.edu
Study contacts (from the official record)
- Rachael Seidler · (734) 834-0385 · rachaelseidler@ufl.edu
- Hunter Stewart · hunter.stewart@ufl.edu
Similar studies in Florida
All healthy volunteers studies in Florida →- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Study of LY4302814 in Healthy Participants
Eli Lilly and Company
- Location
- Daytona Beach, FL
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function
Pfizer
- Location
- Orlando, FL + 3 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
Safety and PK Study of BICX104 With or Without Bupropion Compared to Vivitrol
BioCorRx Pharmaceuticals Inc
- Location
- Miami, FL
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
Arcutis Biotherapeutics, Inc.
- Location
- Miami, FL + 6 other US sites
- Eligibility basics
- Ages 18–65